Which muscarinic receptor is important in the bladder?

T. Yamanishi, C. R. Chappie, R. Chess-Williams

Research output: Contribution to journalArticleResearchpeer-review

79 Citations (Scopus)

Abstract

Antimuscarinic agents are the most widely used therapy for urge incontinence, but have side effects such as constipation, tachycardia and dry mouth, resulting from a lack of selectivity for the bladder. M2 receptors are the predominant cholinoceptors present in urinary bladder, but mainly the minor population of M3 receptors mediate its contraction. M2 receptors modulate detrusor contraction by several mechanisms, and may contribute more to contraction of the bladder in pathological states such as bladder denervation or spinal cord injury. Prejunctional inhibitory M2 or M4 receptors and prejunctional facilitatory muscarinic MI receptors in the bladder have all been reported. In clinical studies, tolterodine, a non-selective muscarinic antagonist, has been reported to be as effective as oxybutynin but inducing less dry mouth. Thus, although it is not certain which antimuscarinic drugs have the better efficacy and tolerability, the non-selective antimuscarinic drugs seem to be better than M3-selective antagonists in their clinical efficacies. However, controlled release, or intravesical, intravaginal, or rectal administrations of oxybutynin have been reported to cause fewer side effects. Darifenacin, a new M3 selective antagonist, has been reported to have selectivity for the bladder over the salivary gland in vivo. To verify which antimuscarinic drugs selective for the muscarinic subtypes have the best efficacy and tolerability, comparative clinical trials between M 3 selective antagonists and non-selective compounds, such as olterodine, are required in the future.

Original languageEnglish
Pages (from-to)299-306
Number of pages8
JournalWorld Journal of Urology
Volume19
Issue number5
DOIs
Publication statusPublished - 1 Jan 2001
Externally publishedYes

Fingerprint

Muscarinic Receptors
Muscarinic Antagonists
Urinary Bladder
Mouth
Intravaginal Administration
Pharmaceutical Preparations
Rectal Administration
Intravesical Administration
Urge Urinary Incontinence
Cholinergic Receptors
Denervation
Constipation
Salivary Glands
Spinal Cord Injuries
Tachycardia
Cholinergic Agents
Clinical Trials
Population

Cite this

Yamanishi, T. ; Chappie, C. R. ; Chess-Williams, R. / Which muscarinic receptor is important in the bladder?. In: World Journal of Urology. 2001 ; Vol. 19, No. 5. pp. 299-306.
@article{b510213c456b4a01ab1aba055517f9d9,
title = "Which muscarinic receptor is important in the bladder?",
abstract = "Antimuscarinic agents are the most widely used therapy for urge incontinence, but have side effects such as constipation, tachycardia and dry mouth, resulting from a lack of selectivity for the bladder. M2 receptors are the predominant cholinoceptors present in urinary bladder, but mainly the minor population of M3 receptors mediate its contraction. M2 receptors modulate detrusor contraction by several mechanisms, and may contribute more to contraction of the bladder in pathological states such as bladder denervation or spinal cord injury. Prejunctional inhibitory M2 or M4 receptors and prejunctional facilitatory muscarinic MI receptors in the bladder have all been reported. In clinical studies, tolterodine, a non-selective muscarinic antagonist, has been reported to be as effective as oxybutynin but inducing less dry mouth. Thus, although it is not certain which antimuscarinic drugs have the better efficacy and tolerability, the non-selective antimuscarinic drugs seem to be better than M3-selective antagonists in their clinical efficacies. However, controlled release, or intravesical, intravaginal, or rectal administrations of oxybutynin have been reported to cause fewer side effects. Darifenacin, a new M3 selective antagonist, has been reported to have selectivity for the bladder over the salivary gland in vivo. To verify which antimuscarinic drugs selective for the muscarinic subtypes have the best efficacy and tolerability, comparative clinical trials between M 3 selective antagonists and non-selective compounds, such as olterodine, are required in the future.",
author = "T. Yamanishi and Chappie, {C. R.} and R. Chess-Williams",
year = "2001",
month = "1",
day = "1",
doi = "10.1007/s003450100226",
language = "English",
volume = "19",
pages = "299--306",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer",
number = "5",

}

Which muscarinic receptor is important in the bladder? / Yamanishi, T.; Chappie, C. R.; Chess-Williams, R.

In: World Journal of Urology, Vol. 19, No. 5, 01.01.2001, p. 299-306.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Which muscarinic receptor is important in the bladder?

AU - Yamanishi, T.

AU - Chappie, C. R.

AU - Chess-Williams, R.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Antimuscarinic agents are the most widely used therapy for urge incontinence, but have side effects such as constipation, tachycardia and dry mouth, resulting from a lack of selectivity for the bladder. M2 receptors are the predominant cholinoceptors present in urinary bladder, but mainly the minor population of M3 receptors mediate its contraction. M2 receptors modulate detrusor contraction by several mechanisms, and may contribute more to contraction of the bladder in pathological states such as bladder denervation or spinal cord injury. Prejunctional inhibitory M2 or M4 receptors and prejunctional facilitatory muscarinic MI receptors in the bladder have all been reported. In clinical studies, tolterodine, a non-selective muscarinic antagonist, has been reported to be as effective as oxybutynin but inducing less dry mouth. Thus, although it is not certain which antimuscarinic drugs have the better efficacy and tolerability, the non-selective antimuscarinic drugs seem to be better than M3-selective antagonists in their clinical efficacies. However, controlled release, or intravesical, intravaginal, or rectal administrations of oxybutynin have been reported to cause fewer side effects. Darifenacin, a new M3 selective antagonist, has been reported to have selectivity for the bladder over the salivary gland in vivo. To verify which antimuscarinic drugs selective for the muscarinic subtypes have the best efficacy and tolerability, comparative clinical trials between M 3 selective antagonists and non-selective compounds, such as olterodine, are required in the future.

AB - Antimuscarinic agents are the most widely used therapy for urge incontinence, but have side effects such as constipation, tachycardia and dry mouth, resulting from a lack of selectivity for the bladder. M2 receptors are the predominant cholinoceptors present in urinary bladder, but mainly the minor population of M3 receptors mediate its contraction. M2 receptors modulate detrusor contraction by several mechanisms, and may contribute more to contraction of the bladder in pathological states such as bladder denervation or spinal cord injury. Prejunctional inhibitory M2 or M4 receptors and prejunctional facilitatory muscarinic MI receptors in the bladder have all been reported. In clinical studies, tolterodine, a non-selective muscarinic antagonist, has been reported to be as effective as oxybutynin but inducing less dry mouth. Thus, although it is not certain which antimuscarinic drugs have the better efficacy and tolerability, the non-selective antimuscarinic drugs seem to be better than M3-selective antagonists in their clinical efficacies. However, controlled release, or intravesical, intravaginal, or rectal administrations of oxybutynin have been reported to cause fewer side effects. Darifenacin, a new M3 selective antagonist, has been reported to have selectivity for the bladder over the salivary gland in vivo. To verify which antimuscarinic drugs selective for the muscarinic subtypes have the best efficacy and tolerability, comparative clinical trials between M 3 selective antagonists and non-selective compounds, such as olterodine, are required in the future.

UR - http://www.scopus.com/inward/record.url?scp=0035514815&partnerID=8YFLogxK

U2 - 10.1007/s003450100226

DO - 10.1007/s003450100226

M3 - Article

VL - 19

SP - 299

EP - 306

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 5

ER -